SOURCE: Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Sep 5, 2012) - Vista Partners announced today that it has initiated coverage on Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) with a $2.05 target price. Ross Silver, Principal Analyst at Vista Partners, stated, "Oculus is growing revenues and recently reported record revenues of $4.1 million for the quarter ending June 30, 2012." Mr. Silver continues, "Oculus seems to be headed towards profitability, possibly in the coming quarter, due to growing revenues and controlling expenses. Oculus and their dermatology partners have successfully introduced three new Microcyn-based products into the U.S. dermatology market for management of atopic dermatitis and other dermatoses. Oculus also announced finalization of their acne drug agreement with AmDerma; concluded site selection and enrolled the first patient for their FDA-reviewed clinical trial for management of scars."
To download a FREE copy of the Oculus Innovative Sciences, Inc. research report, please visit www.vistapglobal.com and complete the research form to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website: www.vistapglobal.com or click here.